Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LS9E
|
|||
| Drug Name |
Durvalumab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Urothelial carcinoma [ICD-11: 2C92.0] | Approved | [1], [2] | |
| Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 3 | [3] | ||
| Biliary tract cancer [ICD-11: 2C17; ICD-10: C24.9] | Phase 2 | [3] | ||
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2 | [3] | ||
| Pancreatic ductal carcinoma [ICD-11: 2C10.0] | Phase 2 | [3] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [3] | ||
| Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Phase 1 | [3] | ||
| Company |
AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death 1 ligand 1 (PD-L1) | Target Info | Modulator | [4] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Reactome | PD-1 signaling | |||
| WikiPathways | Costimulation by the CD28 family | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018 | |||
| REF 2 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.Lancet Oncol. 2018 Apr;19(4):521-536. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.